Immuneering Corp
Data quality: 83%
IMRX
NASDAQ
Manufacturing
Chemicals
$5.31
▼
$0.10
(-1.90%)
6 months return
—
Momentum
Neutral
ROE
-43.61%
Growth
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Quality
Return on Equity
-43.61%
Above sector avg (-54.47%)
ROIC-35.52%
Net MarginN/A
Op. MarginN/A
Safety
Debt / Equity
N/A
Current Ratio24.00
Interest CoverageN/A
Valuation
PE (TTM|NTM)
-6.40 | -4.08
Below sector avg (-1.50)
P/B Ratio1.57
EV/EBITDAN/A
Dividend YieldN/A
Quick Summary
Key Takeaways
Short bullets derived from reported financials—not the AI summary above.
Negative free cash flow of -45.49 M
Price History
Financial Trends
Analyst Price Target
6 analysts
Buy
+220.3%
upside to target
Current
$5.31
Consensus Target
$17.00
$11.00
Low
$30.00
High
Forecast
Forward P/E
-4.08
Forward EPS
-$1.35
Est. Revenue
19.20 M
Earnings Surprises
EPS
Reported
Estimate
Forecast
Next: Q1 2026
·
EPS Est: -$0.25
·
Rev Est: 0.0
| Q12025 | Q22025 | Q32025 | Q42025 | Q1 '26 | Q2 '26 | |
|---|---|---|---|---|---|---|
| Reported | -$0.42 | -$0.40 | -$0.38 | -$0.18 | — | — |
| Estimate | -$0.59 | -$0.40 | -$0.39 | -$0.31 | -$0.25 | -$0.28 |
| Surprise | +28.21% | -0.50% | +2.15% | +42.25% | — | — |
Growth
Rev 5Y: N/A · Earnings 1Y: N/A
Growth
Rev 5Y: N/A · Earnings 1Y: N/A| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
Profitability
ROE: -43.61% · Net Margin: N/A
Profitability
ROE: -43.61% · Net Margin: N/A| Revenue (TTM) | N/A | Net Income (TTM) | -56.02 M |
| ROE | -43.61% | ROA | -39.86% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -45.49 M |
| ROIC | -35.52% | FCF Growth (3Y) | N/A |
Safety
D/E: N/A · Current: 24.00
Safety
D/E: N/A · Current: 24.00| Debt / Equity | N/A | Current Ratio | 24.00 |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | 219.56 M | Tangible Book Value | 220.96 M |
Dividends
Yield: N/A · Payout: N/A
Dividends
Yield: N/A · Payout: N/A| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
Valuation
P/E: -6.40 · EV/EBITDA: N/A
Valuation
P/E: -6.40 · EV/EBITDA: N/A| P/E Ratio | -6.40 | Forward P/E | -4.08 |
| P/B Ratio | 1.57 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | 18.69 | Fwd Earnings Yield | N/A |
| FCF Yield | -12.68% | ||
| Market Cap | 358.82 M | Enterprise Value | 131.26 M |
Per Share
EPS: -1.27 · FCF/Share: -0.70
Per Share
EPS: -1.27 · FCF/Share: -0.70| EPS (Diluted TTM) | -1.27 | Revenue / Share | N/A |
| FCF / Share | -0.70 | OCF / Share | -0.70 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
Efficiency
FCF Conv: 81.19% · CapEx/Rev: N/A
Efficiency
FCF Conv: 81.19% · CapEx/Rev: N/A| CapEx / Revenue | N/A | FCF Conversion | 81.19% |
| SBC-Adj. FCF | -51.80 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | 0.0 | 316,952.0 | 2.08 M |
| Net Income | -56.02 M | -61.04 M | -53.47 M | -50.51 M | -33.54 M |
| EPS (Diluted) | -1.27 | -2.04 | -1.88 | -1.90 | -2.46 |
| Gross Profit | — | — | 0.0 | 158,830.0 | 926,888.0 |
| Operating Income | -59.38 M | -64.07 M | -58.41 M | -51.74 M | -33.89 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 42.05 M | 47.96 M | 41.62 M | 36.27 M | 26.54 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | 324,517.0 | 355,807.0 | — | — | — |
| Interest Expense | — | — | — | — | — |
| Income Tax | 0.0 | — | — | -307,485.0 | -307,485.0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 231.99 M | 52.71 M | 102.58 M | 122.37 M | 166.70 M |
| Total Liabilities | 13.50 M | 11.33 M | 12.01 M | 12.52 M | 10.72 M |
| Shareholders' Equity | 218.48 M | 41.39 M | 90.58 M | 109.85 M | 155.98 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 128.65 M | 36.14 M | 59.41 M | 72.64 M | 74.89 M |
| Current Assets | 176.25 M | 39.59 M | 89.08 M | 108.75 M | 152.33 M |
| Current Liabilities | 10.07 M | 7.50 M | 7.85 M | 8.05 M | 5.63 M |
Peer Comparison
vs Manufacturing sector median (1605 peers)
Compared with similar companies in Manufacturing
Peer Comparison
vs Manufacturing sector median (1605 peers) Compared with similar companies in Manufacturing| Metric | Stock | Sector Median |
|---|---|---|
| P/E | -6.4 | -1.5 |
| P/B | 1.6 | 1.6 |
| ROE % | -43.6 | -54.5 |
| Net Margin % | — | -41.5 |
| Rev Growth 5Y % | — | 1.7 |
| D/E | — | 0.3 |
{"event":"ticker_viewed","properties":{"ticker":"IMRX","listing_kind":"stock","pathname":"/stocks/imrx","exchange":"NASDAQ","country":"US"}}